Pipeline
Curogen is focused on developing first-in-class and best-in-class small molecules and therapeutic protein drugs. Discovering novel targets and utilizing our CR-Fc for multi-target platforms will expand our pipeline to broader indications and target combinations.
| Modality | Program | Indication | Discovery | Preclinical | IND-enabling | Phase 1 | Notes |
|---|---|---|---|---|---|---|---|
| Small molecule | (Small molecule) | Inflammatory Bowel Disease (IBD)* |
|
Phase 1 initiation in 2027 | |||
| Rheumatoid Arthritis (RA)** |
|
||||||
| Multiple Sclerosis (MS)** |
|
||||||
| Therapeutic protein | (Tri-specific TRAP protein) | Hidradenitis Suppurativa (HS)* |
|
Phase 1 & 2a initiation in 2027 | |||
| (Bi & Tri-specific protein) | Inflammatory Bowel Disease (IBD)* |
|
Phase 1 initiation in 2028 | ||||
* Main indication ** Follow-up indication
